Emerging at the UK, retatrutide, a novel peptide , is sparking considerable interest within the scientific community regarding its potential for physique regulation. This dual GIP and GLP-1 target agonist seems to provide a significant improvement over established therapies, showing positive results in early clinical assessments. Researchers sugges